Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Isotope & RadiationFRA:5IR +1.14%92 3-Year EBITDA Growth Rate is 3.80% as of Dec. 2025, which is 58% below its 10-year median of 9.05. GuruFocus rates FRA:5IR with a GF Score™ of 92/100 and a GF Value™ of €1.63. The stock has 5 warning signs investors should review. Among 690 Medical Devices & Instruments companies, China Isotope & Radiation ranks worse than 58.26% on this metric.
During the past 12 months, China Isotope & Radiation's average EBITDA Per Share Growth Rate was 3.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 3.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 8.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of China Isotope & Radiation was 15.20% per year. The lowest was -1.60% per year. And the median was 9.05% per year.
China Isotope & Radiation (FRA:5IR) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
China Isotope & Radiation 3-Year EBITDA Growth Rate Related Terms
FRA:5IR vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, China Isotope & Radiation's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Isotope & Radiation 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, China Isotope & Radiation's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where China Isotope & Radiation's 3-Year EBITDA Growth Rate falls into.
China Isotope & Radiation 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 3.80% mean?
China Isotope & Radiation (FRA:5IR) has a 3-Year EBITDA Growth Rate of 3.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for China Isotope & Radiation and its competitors. This is 58% below median its historical median of 9.05. According to the industry distribution chart, China Isotope & Radiation ranks #402 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 58.3%.
Is China Isotope & Radiation's 3-Year EBITDA Growth Rate too high?
China Isotope & Radiation's current 3-Year EBITDA Growth Rate of 3.80% is 58% below median its 10-year median of 9.05. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.10. China Isotope & Radiation's value of 3.80% is 53.1% below this industry median. Based on the distribution chart, China Isotope & Radiation ranks #402 out of 690 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, China Isotope & Radiation has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Isotope & Radiation's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, China Isotope & Radiation ranks #402 out of 690 companies for 3-Year EBITDA Growth Rate. This places China Isotope & Radiation in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.10. China Isotope & Radiation's value of 3.80% is 53.1% below this benchmark. While the company's 10-year median is 9.05 vs. the industry median of 8.10, China Isotope & Radiation has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.10, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Isotope & Radiation's current 3-Year EBITDA Growth Rate of 3.80% is 53.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for China Isotope & Radiation and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Isotope & Radiation's current 3-Year EBITDA Growth Rate is 3.80%, which is 58% below median its own 10-year median of 9.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Isotope & Radiation stock overvalued right now?
China Isotope & Radiation (FRA:5IR) has a current 3-Year EBITDA Growth Rate of 3.80%. The stock's GF Value™ is €1.63, compared to a current price of €1.77 — trading 8.6% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 3.80%, which is 58% below median its 10-year median of 9.05 and 53.1% below the Medical Devices & Instruments industry median of 8.10. China Isotope & Radiation's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For China Isotope & Radiation (FRA:5IR), the current 3-Year EBITDA Growth Rate is 3.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Isotope & Radiation (FRA:5IR) Overvalued in 2026?
Based on GuruFocus' analysis, China Isotope & Radiation stock appears to be overvalued.
The current stock price of €1.77 is trading 8.6% above its estimated GF Value™ of €1.63.
Key valuation signals for FRA:5IR:
3-Year EBITDA Growth Rate: 3.80% (58% below median its 10-year median of 9.05)
GF Value™: €1.63 vs. price of €1.77 (8.6% above fair value)
Industry Position: 53.1% below the Medical Devices & Instruments median (#402 of 690)
No single metric tells the full story. See the FRA:5IR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Isotope & Radiation Corp is a Chinese company. It has five operating segments: (1) nuclear medicine; (2) radioactive source products; (3) irradiation; (4) nuclear medical equipment and related services; and (5) other businesses. Nuclear medicines: manufacturing and sale of a range of imaging diagnostic and therapeutic radio pharmaceuticals imaging, UBT diagnostic kits and test analysers and other products. Its radioactive source products segment involves the sale of medical and industrial radioactive source products and technical services. The company's operations are carried out and a majority of its customers are located in the PRC.
92GF Score
Get the complete analysis for FRA:5IR
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5IR has been successfully added to your 
